Shares of Liquidia Technologies Inc (LQDA) surged 5.62% in pre-market trading on Monday following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical company, focused on developing treatments for pulmonary arterial hypertension (PAH) and other respiratory diseases, significantly outperformed market expectations.

Liquidia reported Q3 revenue of $54.342 million, dramatically surpassing the analyst consensus estimate of $18.8 million. This represents a staggering 1,120% increase compared to the same period last year when the company posted revenues of $4.448 million. The substantial growth was primarily driven by strong sales of YUTREPIA, Liquidia's inhaled dry-powder formulation of treprostinil, which generated $51.7 million in net product sales during its first full quarter on the market.

The company's bottom line also showed significant improvement. Liquidia reported a net loss of $3.5 million, or $0.04 per share, compared to a loss of $31.0 million, or $0.40 per share, in the same quarter of 2024. This beat the analyst expectations of a $0.40 loss per share. Moreover, Liquidia achieved profitability on an operating basis, with $1.7 million in operating income and positive non-GAAP adjusted EBITDA of $10.1 million. The strong financial performance, coupled with growing adoption of YUTREPIA among patients and healthcare providers, has boosted investor confidence in Liquidia's growth prospects, leading to the pre-market stock surge.